101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease
101 Therapeutics Ltd. today announced the public release of its clinical and scientific evidence package for 101-PGC-005 (‘005), a macrophage-targeted dexamethasone prodrug designed to modulate pathogenic CD206-positive macrophage inflammation while preserving systemic immune function.
